Transgene and PersonGen Announce Collaboration to Evaluate a New Combination Therapy Against Solid Tumors
18 Janvier 2022 - 05:45PM
Business Wire
Collaboration to Evaluate the Combination of Transgene’s
Oncolytic Virus and PersonGen’s CAR-T Cells in Preclinical
Models
Regulatory News:
Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech
company that designs and develops virus-based immunotherapeutics
against cancer, and PersonGen BioTherapeutics, a Chinese
biotech company at clinical trial stage, which is developing
breakthrough and innovative CAR-T cell therapies for solid tumors
and hematologic tumors, today announced a strategic
collaboration to evaluate the feasibility and efficacy of
combination therapy associating PersonGen's TAA06 CAR-T cell
injection with intravenous (IV) administration of an armed
oncolytic virus, from Transgene’s Invir.IO™ platform, in solid
tumors including pancreatic cancer and brain glioma. The
collaboration aims to demonstrate the combination’s likely
synergistic mechanisms to potentiate CAR-T cell therapy.
Under the terms of the collaboration agreement, Transgene
will develop multiple new OV candidates, using its patented
oncolytic virus backbone VVcopTK-RR- and its Invir.IO™ technology
platform, specifically for IV administration in combination
with PersonGen's TAA06 CAR-T injection. PersonGen will evaluate the
efficacy of the combination to eliminate solid tumors in
preclinical models.
While CAR-T cell drugs have achieved great success in the
treatment of hematological tumor therapies, there are many clinical
challenges with the use of these novel therapies to treat solid
tumors. One of the most critical obstacles is that the solid tumor
microenvironment not only obstructs the homing of CAR-T cells, but
also inhibits CAR-T cells' function. In addition, the high
heterogeneity of solid tumors also facilitates immune escape from
CAR-T cell therapy.
TAA06, has been independently developed by PersonGen, which has
filed an investigational new drug (IND) application for this novel
CAR-T therapy in China and will initiate the IND in the US later
this year. Preclinical studies with TAA06, including
pharmacodynamic data have shown superior in vivo and in vitro
therapeutic efficacy in solid tumors.
Patented VVcopTK-RR- oncolytic viruses developed with
Transgene’s Invir.IO™ platform are able to:
- selectively replicate in cancer cells leading to tumor
lysis;
- effectively release antitumor payloads into the tumor;
- stimulate an immune response locally in the tumor, thus
optimizing the safety profile of the virus with the added potential
to transform a “cold” tumor into a “hot” tumor.
Clinical and preclinical data has demonstrated that after IV
administration, VVcopTK-RR- oncolytic viruses selectively replicate
and persist in tumor cells leading to the local expression of its
functional payload1.
Based on these highly supportive data, Transgene and
PersonGen believe that combining Transgene’s OV and PersonGen’s
CAR-T therapies could overcome the challenges of solid tumor
heterogeneity by improving the tumor microenvironment.
***
About Transgene Transgene (Euronext: TNG) is a
biotechnology company focused on designing and developing targeted
immunotherapies for the treatment of cancer. Transgene’s programs
utilize viral vector technology with the goal of indirectly or
directly killing cancer cells. The Company’s clinical-stage
programs consist of two therapeutic vaccines (TG4001 for the
treatment of HPV-positive cancers, and TG4050, the first
individualized therapeutic vaccine based on the myvac® platform) as
well as two oncolytic viruses (TG6002 for the treatment of solid
tumors, and BT-001, the first oncolytic virus based on the
Invir.IO™ platform). With Transgene’s myvac® platform, therapeutic
vaccination enters the field of precision medicine with a novel
immunotherapy that is fully tailored to each individual. The myvac®
approach allows the generation of a virus-based immunotherapy that
encodes patient-specific mutations identified and selected by
Artificial Intelligence capabilities provided by its partner NEC.
With its proprietary platform Invir.IO™, Transgene is building on
its viral vector engineering expertise to design a new generation
of multifunctional oncolytic viruses. Transgene has an ongoing
Invir.IO™ collaboration with AstraZeneca. Additional information
about Transgene is available at: www.transgene.fr. Follow us on
Twitter: @TransgeneSA
About PersonGen PersonGen’s vision and goal are to
develop high-quality cellular therapeutics that cancer patients
really need. Founded in 2010, PersonGen has turned into a
state-level high-tech enterprise focusing on R&D of
breakthrough and innovative cellular immunotherapy technology and
drug products for cancers. The company is dedicated to developing
first-in-class and best-in-class CAR-T cell drugs. The Headquarter
and the R&D Center (PersonGen -Suzhou is located in SIP,
Suzhou, Jiangsu Province; the Industrial Cell Manufacturing Center
(PersonGen-Anke) is located in Hefei, Anhui Province; and a newly
formed Center for Cell Preparation and Supply is located in
Shijiazhuang, Hebai Province, which aims to have northern part of
China covered under its service supply-chain. Since its inception,
the company has continuously gained the favor of investors. In
2012, PersonGen received angel round investment from Suzhou
Industrial Park (SIP) Leading Venture Capital, Suzhou Industrial
Park Venture Capital Guide Fund and other partners. In 2015 and
2016, it received strategic investment from Anhui Anke
Biotechnology (Group) Co.,Ltd.. At the beginning of 2021, PersonGen
(Suzhou) and PersonGen-Anke completed a major internal
restructuring and followed by A round of investment of nearly 100
million yuan from YuanBio Venture Capital, Puenguoxin Equity
Investment and Sangel Capital. At the end of 2021, the restructured
PersonGen attracted B round financing of over 200 million yuan
co-led by CCIC and Huatai Securities, and co-invested by Panyi
Capital and Huatong Capital. This B round investment provides a
greater impetus for the further development of PersonGen. With its
first-class R&D capabilities on cell therapy drugs, its
automatic CAR-T cell preparation pipeline, and advanced lentiviral
vector industrial process system, PersonGen has successfully
developed several first-in-class and best-in-class therapeutic cell
products, covering most hematological tumors and some solid tumors.
Among them, first-in-class PA3-17 injection for T-lymphoblastic
leukemia/lymphoma is the first autologous CD7-CAR-T cell drug
candidate in the world that was approved for registered clinical
trials, and it was designated as an orphan drug by the US FDA; the
TAA06 CAR-T cell injection, developed for treating solid tumors in
children and adults, has demonstrated outstanding tumor clearance
efficacy in preclinical studies, and is now entering into the IND
application phase in China. For more information, please visit
www.persongen.com.
Transgene disclaimer This press release contains
forward-looking statements, which are subject to numerous risks and
uncertainties, which could cause actual results to differ
materially from those anticipated. The occurrence of any of these
risks could have a significant negative outcome for the Company’s
activities, perspectives, financial situation, results, regulatory
authorities’ agreement with development phases, and development.
The Company’s ability to commercialize its products depends on but
is not limited to the following factors: positive pre-clinical data
may not be predictive of human clinical results, the success of
clinical studies, the ability to obtain financing and/or
partnerships for product manufacturing, development and
commercialization, and marketing approval by government regulatory
authorities. For a discussion of risks and uncertainties which
could cause the Company’s actual results, financial condition,
performance, or achievements to differ from those contained in the
forward-looking statements, please refer to the Risk Factors
(“Facteurs de Risque”) section of the Universal Registration
Document, available on the AMF website (http://www.amf-france.org)
or on Transgene’s website (www.transgene.fr). Forward-looking
statements speak only as of the date on which they are made, and
Transgene undertakes no obligation to update these forward-looking
statements, even if new information becomes available in the
future.
1 Cassier et al. “Bioavailability and activity of oncolytic
virus TG6002 after intravenous administration in patients with
advanced gastrointestinal carcinomas” ESMO 2021, 16–21 September
2021, Poster presentation; Bendjama et al. “Oncolytic virus TG6002
locates to tumors after intravenous infusion and induces
tumor-specific expression of a functional pro-drug activating
enzyme in patients with advanced gastrointestinal carcinomas” 2021
AACR Annual Meeting, April 9-14, 2021, Poster presentation
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220118005851/en/
Transgene: Jean-Philippe Del Chief Financial Officer +33
(0)3 88 27 91 00 investorrelations@transgene.fr Media:
MEDiSTRAVA Consulting David Dible/Sylvie Berrebi +44 (0)7714
306525 transgene@medistrava.com
PersonGen: Dr Nan Yang VP, Business Development
nan.yang@persongen.com
Transgene (EU:TNG)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024
Transgene (EU:TNG)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024